BioVie Shares Up 31% Premarket; Co To Present Blinded Data On NE3107 In Treatment Of Mild To Moderate Alzheimers Disease At CTAD At 12:20 PM ET Wednesday
Portfolio Pulse from Charles Gross
BioVie is set to present blinded data on NE3107, a treatment for mild to moderate Alzheimer's disease, at the Clinical Trials on Alzheimer's Disease (CTAD) conference. The company's shares are up 31% in premarket trading.
October 25, 2023 | 9:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioVie's stock is up 31% premarket ahead of the company's presentation of data on its Alzheimer's treatment at the CTAD conference.
The surge in BioVie's stock price is likely due to investor anticipation of the company's presentation at the CTAD conference. Positive data on the company's Alzheimer's treatment could potentially boost the stock further.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100